The Medicinal Cannabis Research Collaboration (MCRC) is a premier Contract Research Organisation (CRO) and collaboration between Cannvalate and a leading Australian University – a joint enterprise between a distinguished Australian medicinal cannabis company and world-renowned researchers. The MCRC is one of the only true medicinal cannabis research specialists in the world.
We have combined the award winning medicinal cannabis experience from Cannvalate with well established researchers and advanced research facilities.
Our vision is to be your end-to-end trusted partner in medicinal cannabis clinical trials and research.
Our mission is to provide University-led intelligent and innovative turn-key solutions to our medicinal cannabis partners ensuring that clinical trials are conducted economically with the highest compliance, quality and efficiency. We accomplish this through collaborative and synergistic partnerships that are based on the fundamentals of understanding your business and your specific challenges, operating with absolute integrity, proactivity and transparency.
The MCRC Contract Research Organisation, part of the Cannvalate group was formed shortly after the legalisation of medicinal cannabis in Australia in collaboration with a leading Australian University who shares a passion for delivering outstanding data in this specialty area.
Born due to the appetite for quality medicinal cannabis data from both government and private markets, the MCRC have dedicated their efforts and knowledge to becoming specialists in medicinal cannabis R&D. Now partnering with local and international sponsors to deliver novel drug development, register products and obtaining quality data.
An Australian Cannabis Biotech CEO approached MCRC looking for a suite of clinical trials to bring their product to registration with the ARTG (Australian Register of Therapeutic Goods). “MCRC quickly understood our needs, defined the regulatory strategy, created the eCTD dossier, developed a robust protocol, organised HREC approval, oganised the delivery of our Investigative Product to their secure site and we are now ready to commence our Schedule 3 CBD program. We highly recommend MCRC for your specialist medicinal cannabis trials and programs.”
“We have strategically partnered with MCRC on two medicinal cannabis clinical trials. MCRC have provided excellent service, sound medical, scientific and regulatory advice ensuring that we landed on the optimal trial design to hit our primary and secondary outcomes.”
Blaise Bratter – Global Sales Manager, MGC Pharmaceuticals
“Having been involved in the pharmaceutical business for over 18 years it is always great to work with a company who are innovative and ambitious, the team at Cannvalate are a pleasure to deal with and their knowledge is second to none. From day one our working relationship they have been proactive, dynamic and all tasks were completed with understanding and minimum ease. I look forward to working with the Cannvalate team into the future”
Caroline Glynn Co-Founder & CSO
“We undertook a Strategic Assessment Workshop led by MCRC, the panel of doctors who partook in the research and presentation of the workshop were consummate professionals who were exceptionally knowledgeable in their specialty areas. We look forward to taking the next step in our clinical research study plans under the guidance of MCRC.”
Dan Casey, Managing Director, Greenfern Industries (New Zealand)